HCV Retreatment May Be Successful After Switching From An NS5A Inhibitor DAA To A Protease Inhibitor, Researchers Say

Healio (12/10, Bennett) reports, “Patients who failed to achieve sustained virologic response after initial treatment for hepatitis C [HCV] achieved high cure rates during retreatment after switching from an NS5A inhibitor direct-acting antiviral [DAA] to...